Study of family medicine role in breast cancer prevention: A systematic review

Sadr, Zahra; Moghaddam, Mehrnaz Jamali; Rouhani, Hamideh Sabet; Saniee, Nadia; Abhari, Maryam Biglari

doi:10.34172/jpe.2021.32

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Asian BCa Association reported that 13% of the women diagnosed with BCa were 40 years old, and 5% were 35 years old [5,6]. BCa is considered more common as people get older, due to the accumulation of somatic mutations in the mammary glands [7,8]. In 2018, approximately 266,120 women will be detected with invasive BCa in the United States, while 63,960 will be detected with in situ BCa.…”

Section: Introductionmentioning

confidence: 99%

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Yang

Zhang

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

After skin malignancy, breast cancer is the most widely recognized cancer detected in women in the United States. Breast cancer (BCa) can happen in all kinds of people, but it's much more common in women. One in four cases of cancer and one in six deaths due to cancer are related to breast cancer. Angiogenesis is an essential factor in the growth of tumors and metastases in various malignancies. An expanded level of angiogenesis is related to diminished endurance in BCa patients. This function assumes a fundamental part inside the human body, from the beginning phases of life to dangerous malignancy. Various factors, referred to as angiogenic factors, work to make a new capillary. Expanding proof demonstrates that angiogenesis is managed by microRNAs (miRNAs), which are small non-coding RNA with 19–25 nucleotides. MiRNA is a post-transcriptional regulator of gene expression that controls many critical biological processes. Endothelial miRNAs, referred to as angiomiRs, are probably concerned with tumor improvement and angiogenesis via regulation of pro-and anti-angiogenic factors. In this article, we reviewed therapeutic functions of miRNAs in BCa angiogenesis, several novel delivery carriers for miRNA-based therapeutics, as well as CRISPR/Cas9 as a targeted therapy in breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Yang

Zhang

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Furthermore, in Stoff Khalili et al research, hMSCs were utilized as intermediate vehicles for conditional replication oncolytic adenoviruses (CRAds) to target breast cancer and reduced the development of pulmonary metastasis, most likely due to viral replication in the hMSCs [ 90 ]. Pulmonary metastasis in patients with breast cancer is common characteristic [ 171 , 172 , 173 ] and is associated with lethal complications in these patients [ 174 , 175 ]. Furthermore, when CRAd-loaded MSC was given intravenously to mice with solid ovarian cancer, it had a considerably stronger anticancer impact and a prolonged survival time than CRAd delivered directly [ 89 ].…”

Section: Msc-based Delivery Of Oncolytic Adenovirus (Oads)mentioning

confidence: 99%

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

et al. 2023

View full text Add to dashboard Cite

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no damage to normal cells in the process. Because of their specific features, such as, the ability to induce immunogenic cell death and to contain curative transgenes in their genomes, OVs have attracted attention as candidates to be utilized in cooperation with immunotherapies for cancer treatment. This treatment takes advantage of most tumor cells' inherent tendency to be infected by certain OVs and both innate and adaptive immune responses are elicited by OV infection and oncolysis. OVs can also modulate tumor microenvironment and boost anti-tumor immune responses. Mesenchymal stem cells (MSC) are gathering interest as promising anti-cancer treatments with the ability to address a wide range of cancers. MSCs exhibit tumor-trophic migration characteristics, allowing them to be used as delivery vehicles for successful, targeted treatment of isolated tumors and metastatic malignancies. Preclinical and clinical research were reviewed in this study to discuss using MSC-released OVs as a novel method for the treatment of cancer.

show abstract

Study of family medicine role in breast cancer prevention: A systematic review

Cited by 2 publications

References 14 publications

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Contact Info

Product

Resources

About